{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioavailability+Study&page=26",
    "query": {
      "condition": "Bioavailability Study",
      "page": 26
    },
    "page_size": 10
  },
  "pagination": {
    "page": 26,
    "page_size": 10,
    "total_count": 1099,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioavailability+Study&page=27&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bioavailability+Study&page=25&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-28T13:05:40.129Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01260155",
      "title": "A Single-Center, Open-Label, Randomized, 3-Treatment Crossover Bioavailability Study of Single Oral Doses of E5501 Old Tablet Formulation Under Fasted Conditions and a New Tablet Formulation Under Fed and Fasted Conditions in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "E5501",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 16,
      "start_date": "2010-01",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2013-11-01",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 1,
      "location_summary": "Phoenix, Arizona",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01260155"
    },
    {
      "nct_id": "NCT05776108",
      "title": "A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cabotegravir IR Formulation (reference)",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir DT Formulation (test 1)",
          "type": "DRUG"
        },
        {
          "name": "Cabotegravir DT Formulation (test 2)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-03-23",
      "completion_date": "2023-06-08",
      "has_results": false,
      "last_update_posted_date": "2023-12-13",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05776108"
    },
    {
      "nct_id": "NCT04886050",
      "title": "Relative Bioavailability Study to Assess an LC350189 Tablet Compared to an LC350189 Capsule in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gout",
        "Hyperuricemia"
      ],
      "interventions": [
        {
          "name": "LC350189 Tablet",
          "type": "DRUG"
        },
        {
          "name": "LC350189 Capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LG Chem",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 23,
      "start_date": "2021-07-31",
      "completion_date": "2021-12-10",
      "has_results": false,
      "last_update_posted_date": "2022-01-06",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 1,
      "location_summary": "Las Vegas, Nevada",
      "locations": [
        {
          "city": "Las Vegas",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04886050"
    },
    {
      "nct_id": "NCT04922593",
      "title": "Relative Bioavailability of LY03010 Compared to Listed Drug",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia",
        "Psychotic Disorders",
        "Mood Disorders",
        "Schizophrenia Spectrum",
        "Mental Disorders",
        "Antipsychotic Agents",
        "Tranquilizing Agents",
        "Central Nervous System Depressants",
        "Physiological Effects of Drugs",
        "Psychotropic Drugs",
        "Neurotransmitter Agents",
        "Molecular Mechanisms of Pharmacological Action"
      ],
      "interventions": [
        {
          "name": "LY03010; paliperidone palmitate",
          "type": "DRUG"
        },
        {
          "name": "INVEGA SUSTENNA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Luye Pharma Group Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 281,
      "start_date": "2021-01-13",
      "completion_date": "2022-04-15",
      "has_results": false,
      "last_update_posted_date": "2023-04-25",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 9,
      "location_summary": "Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Lemon Grove",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04922593"
    },
    {
      "nct_id": "NCT05179525",
      "title": "Comparative Bioavailability of Risperidone.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Schizophrenia"
      ],
      "interventions": [
        {
          "name": "Risperidone ISM® 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Risperdal 4mg Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rovi Pharmaceuticals Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 80,
      "start_date": "2021-03-09",
      "completion_date": "2021-09-17",
      "has_results": false,
      "last_update_posted_date": "2022-01-05",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 4,
      "location_summary": "Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more",
      "locations": [
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "Gaithersburg",
          "state": "Maryland"
        },
        {
          "city": "Berlin",
          "state": "New Jersey"
        },
        {
          "city": "DeSoto",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05179525"
    },
    {
      "nct_id": "NCT04565678",
      "title": "A Study to Assess the Relative Bioavailability and Effect of Food on the Coated Granule Formulation of Mitapivat in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Mitapivat tablets",
          "type": "DRUG"
        },
        {
          "name": "Mitapivat coated granules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Agios Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2020-09-21",
      "completion_date": "2020-12-03",
      "has_results": false,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04565678"
    },
    {
      "nct_id": "NCT06916143",
      "title": "Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "LY4100511",
          "type": "DRUG"
        },
        {
          "name": "Rabeprazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1,
      "start_date": "2025-04-08",
      "completion_date": "2025-04-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 2,
      "location_summary": "Miami, Florida • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06916143"
    },
    {
      "nct_id": "NCT02189252",
      "title": "An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Epanova",
          "type": "DRUG"
        },
        {
          "name": "Lovaza",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-10",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-06-20",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 3,
      "location_summary": "Kansas City, Kansas • Cincinnati, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02189252"
    },
    {
      "nct_id": "NCT01366547",
      "title": "Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects",
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg",
          "type": "DRUG"
        },
        {
          "name": "Dolutegravir 50 mg",
          "type": "DRUG"
        },
        {
          "name": "abacavir 600 mg/lamivudine 300 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 18,
      "start_date": "2011-06",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2011-08-08",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01366547"
    },
    {
      "nct_id": "NCT03846843",
      "title": "OCR002-SP103 - Oral Immediate Release Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cirrhosis"
      ],
      "interventions": [
        {
          "name": "OCR-002 IR Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "OCR-002 Oral Solution",
          "type": "DRUG"
        },
        {
          "name": "OCR-002 IV Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ocera Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2016-08-15",
      "completion_date": "2017-12-31",
      "has_results": false,
      "last_update_posted_date": "2021-09-20",
      "last_synced_at": "2026-10-28T13:05:40.129Z",
      "location_count": 1,
      "location_summary": "Coronado, California",
      "locations": [
        {
          "city": "Coronado",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03846843"
    }
  ]
}